GRN collaborates in one of the largest clinical trials in genomic medicine.
Specific gene could predict colon cancer outcomes. Article published with Nature Communications


Accelerating cures for cancer, bringing precision medicine to your community, eliminating disparities.

Guardian Research Network (GRN) is a nationwide consortium of high-performing community health systems that created a 21st century breakthrough platform for accelerating cures for cancer. GRN harnesses the power of big data to aggregate hundreds of thousands of patient clinical and molecular profiles into a dynamic knowledge architecture focused on the rapid identification of populations to deliver targeted and novel clinical therapies. GRN’s goals are to expand patient access to leading therapies without leaving home; enhance precision medicine in local communities; democratize clinical trial access, with special benefit to underserved populations; and radically improve the drug approval process. GRN founding members include: Gibbs Cancer Center & Research Institute, Spartanburg, SC; Baptist Health, Louisville, KY; Mercy, Saint Louis, MO; and the Bon Secours Health System, Marriottsville, MD.

GRAIL Cancer Detection Research Draws $900M from Investors

In December, it was announced that the Guardian Research Network (GRN) was collaborating with life…

read more

Guardian Research Network Joins GRAIL Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early

Guardian Research Network has joined a multi-center clinical team organized by GRAIL, Inc., a life…

read more